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Abstract
Background: Cervical cancer is a major mortality factor in the female population. This neoplastic is an excellent
model for studying the mechanisms involved in cancer maintenance, because the Human Papilloma Virus (HPV) is
the etiology factor in most cases. With the purpose of characterizing the effects of malignant transformation in
cellular activity, proteomic studies constitute a reliable way to monitor the biological alterations induced by this
disease. In this contextual scheme, a systemic description that enables the identification of the common events
between cell lines of different origins, is required to distinguish the essence of carcinogenesis.
Results: With this study, we sought to achieve a systemic perspective of the common proteomic profile of six
cervical cancer cell lines, both positive and negative for HPV, and which differ from the profile corresponding to
the non-tumourgenic cell line, HaCaT. Our objectives were to identify common cellular events participating in
cancer maintenance, as well as the establishment of a pipeline to work with proteomic-derived results. We
analyzed by means of 2D SDS-PAGE and MALDI-TOF mass spectrometry the protein extracts of six cervical cancer
cell lines, from which we identified a consensus of 66 proteins. We call this group of proteins, the “central core of
cervical cancer”. Starting from this core set of proteins, we acquired a PPI network that pointed, through
topological analysis, to some proteins that may well be playing a central role in the neoplastic process, such as 14-
3-3ζ. In silico overrepresentation analysis of transcription factors pointed to the overexpression of c-Myc, Max and
E2F1 as key transcription factors involved in orchestrating the neoplastic phenotype.
Conclusions: Our findings show that there is a “central core of cervical cancer” protein expression pattern, and
suggest that 14-3-3ζ is key to determine if the cell proliferates or dies. In addition, our bioinformatics analysis
suggests that the neoplastic phenotype is governed by a non-canonical regulatory pathway.
Background
The definition of cancer has evolved according to the
knowledge and perspective of the scientific context in
which it is conceived. It has changed from a highly het-
erogeneous disease seen from a cell type and tissue of
origin point of view, to the conception of cancer as an
illness that involves the deregulation of various pathways
that govern key, and somewhat common, cellular pro-
cesses [1]. Particularly, in 2000 Hanahan and Weinberg
suggested that all cancer types represent a manifestation
of six essential alterations in cell physiology that
collectively coordinate the malignant phenotype: self-
sufficiency in growth signals, insensitivity to growth
inhibitors, evasion of programmed cell death, increase of
the replicative potential, sustained angiogenesis and tis-
sue invasion and metastasis [2]. Furthermore, in a recent
review published by the same two authors, they pro-
posed two emerging hallmarks: reprogramming of
energy metabolism and evading immune destruction;
besides suggesting genomic instability and mutations, as
well as tumor-promoting inflammation, as enabling
characteristics [3].
Regardless of the latter, several cancer types have been
more intensively studied due to their penetrance in the
human population, such as prostate and breast cancer.
However, we see in cervical cancer a unique opportunity
to study the malignant transformation because of its
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quence of High-Risk Human Papilloma Virus (HR-HPV)
infection, according to a study carried out in nine coun-
tries of diverse cervical cancer incidences [4]. HR-HPVs
encode the E6 and E7 oncoproteins, which interact with
the well known and very common, tumor suppressor
proteins p53 and pRB, respectively; among several other
proteins that together impart a very strong oncogenic
potential to the virus [5-7].
To date 120 types of human papillomaviruses have
been identified, which can be subdivided into low-risk
types, found mainly in genital warts, and high-risk types,
which are frequently associated with invasive cervical
cancer [8]. Among the high-risk types HPV16 and
HPV18 are the most prevalent, present in 54.6% and
11% of squamous cervical carcinomas, respectively [4].
This is part of the reason why, cervical cancers derived
from patients infected with those viral types, have been
intensively studied, and one of the best studied human
cell line, HeLa, is positive for HPV18 [9]. Likewise, it is
pertinent to mention that there are other cell lines
which originated from HPV negative cervical cancers
that have also been widely studied and therefore, enable
the visualization of alterations in protein expression,
common to many cervical cancer cell lines indepen-
dently of their origin.
Cervical cancer is one of the most common types of
cancer and a major mortality factor of women world-
wide [4]. Because most of the cases are a consequence
of viral infections, cervical cancer is a disease that has
been successfully addressed in developed countries
thanks to preventive medicine [10]. Nonetheless, when
left unattended, a persistent viral infection combined
with a strong and constitutive expression of viral onco-
proteins E6 and E7 are highly inductive steps towards
the malignant transformation of cervical epithelium [5].
However, owing to a frequent and spontaneous elimina-
tion of viral sequences, not all the patients infected with
HR-HPV develop cervical cancer [11]. This indicates
that most HPV infections are subclinical and only a
small fraction of HR-HPV infections produce early
epithelial lesions, and a more modest fraction of those
lesions will develop into cancer. Consequently, even if
infection by HR-HPV can be considered as the initial hit
that gives rise to cervical cancer, the superseding steps
that enable cancer development have not yet been
described [12].
Currently, an accurate prediction of the evolution of
t h et u m o ri so n eo ft h eb i g g e s tc h a l l e n g e sf o rc l i n i c a l
oncology. Because of this, the conception of an integra-
tive model that enables the prediction of future states of
a system has become of vital importance. We consider
that one of the best approaches currently available to
accomplish this task are protein-protein interactions
(PPI), because they encompass the scaffold of molecular
pathways and cellular processes, besides being capable
of revealing the dynamic and interactive function of
human proteins [13]. Furthermore, available databases
of some organisms have promoted the construction of
networks which become the starting point to explore
and infer the fundamental principles by which the cell
orchestrates its response to different kinds of
perturbations.
In this work, we developed a pipeline for the func-
tional analysis of differentially expressed proteins in cer-
vical cancer compared with a non-cancerous control
and obtained from 2D SDS-PAGE. We used PPI net-
works, pathways and GOs enrichment analysis, suc-
ceeded by an analysis of the promoter gene sequences
to get a more systemic point of view of cervical cancer.
We consider that the main advantage of following this
approach is that it enabled to explore and locate impor-
tant proteins for the biological phenomenon, which
could have been overlooked as a consequence of the
experimental methodology used, because some proteins
are present in low concentrations or posses isoelectric
points or molecular weights located outside the electro-
phoretic resolution range utilized in 2D SDS-PAGE.
Results
A conserved protein expression pattern exists in cervical
cancer cell lines
Protein extracts of the six cancer cell lines: two cell lines
which are positive for infection with HPV type 18 (HeLa
and CaLo), two positive for HPV type 16 (SiHa and
CasKi), and two HPV negative (ViBo and C-33A); and
HaCaT, a spontaneously immortalized keratinocyte cell
line we used as control, were obtained and analyzed by
2D SDS-PAGE (Figure 1). In our opinion, this experi-
mental design permitted the identification of proteins
that are common to the neoplastic phenotype regardless
of the presence of intrinsic variations, such as a virus.
We set the HaCaT cell line as a control because it is of
epithelial origin and has an extended replicative poten-
tial, which allows us to distinguish between the biologi-
cal events of transformation and immortality. Also, it
has been widely used as a control in several studies of
cervical cancer [14].
Three independent analyses were performed and used
for protein profiling. For each sample, 2-D gel electro-
phoresis was carried out in a pH range of 3 to 10. The
Coomassie-stained gels were acquired with densitometer
GS-800 (Bio-Rad) and analyzed using PD-Quest soft-
ware v 8.0.1. On average, more than 1,000 protein spots
were revealed in each 2-DE gel. The quantity of each
spot in a gel was normalized as a percentage of the total
quantity in the map, according to its optical density
(OD) value. We focused on the electrophoretic entities
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not appear in the HaCaT control, or those which chan-
ged consistently and significantly (more than 2-fold).
We call this group of 127 proteins, the “central core of
cervical cancer”. Among the 127 spots analyzed, 98 pro-
teins were identified based on their tryptic peptide
masses using the MALDI-TOF equipment, resulting in
66 unique proteins. (Table 1).
Since this study pointed to a “central core of cervical
cancer”, it was necessary to understand the nature of
the proteins involved in the process. To this end, 66
proteins were classified via GO (Gene Ontology) using
QuickGo of EMBL-EBI database [15]. The identities of
the proteins of the central core confirm that these are
important in cancer because several studies have linked
their aberrant expression to the neoplastic phenotype.
With reference to their assigned functions, these pro-
teins can be divided into at least three groups:
The first group includes proteins related to cell migra-
tion and metastasis, like anexin 2 that plays a crucial
role in establishing metastasis of prostate cancer (PCa)
by regulating the adhesion and migration of PCa to
osteoblasts and endothelial cells [16]; protein disulfide-
isomerase which is strongly expressed by invasive glioma
cells, and its inhibition led to reduced glioma cell migra-
tion and invasion [17]; vimentin, an intermediate fila-
ment cytoskeletal protein and a marker of Epithelial
Mesenchymal Transition (EMT), contributes to invasion
and metastasis in prostate cancer [18]; ezrin is required
for invasion and metastasis of mammary carcinoma
[19]; and finally vinculin, which facilitates contractile
force generation, enhancing cell invasion [20]. This
group of proteins could be a sign of invasion and metas-
tasis in cervical cancer, similar to their role in other
cancer types.
In a second group, we placed proteins related to eva-
sion of apoptosis: GRP78, HSP71, HSP7C, HS90B and
GRP75. These proteins are activated as part of the
Unfolded Proteins Response (UPR), which has been lar-
gely related to survival, cell proliferation and angiogen-
esis [21]. Likewise, it has been shown that
overexpression of GRP78 is sufficient to confer apopto-
sis resistance in at least two cell types, regardless of its
function within the UPR [22]. We believe these proteins
could be a link between different hallmarks of cancer,
like apoptosis evasion, angiogenesis and proliferation.
In a third group, we find proteins involved in or asso-
ciated with central metabolism like glyceraldehyde 3
Figure 1 Pipeline. We compared the protein profiles of six cervical cancer cell lines by 2D SDS-PAGE, and established a set of proteins common
to these cell lines, and which did not feature in our control. This set of proteins was termed “central core of cervical cancer”, (a). From the
central core, we reconstructed a PPI network (b), this network expanded and used to obtain the overrepresented GO’s and pathways. Finally, we
conducted an analysis of the transcription factors contained in the extended network using ChIP-Seq analysis of the ENCODE project (c).
Higareda-Almaraz et al. BMC Systems Biology 2011, 5:96
http://www.biomedcentral.com/1752-0509/5/96
Page 3 of 16Table 1 Proteins identified as members of the “central core of cervical cancer”
Accession number Name Score Expect Searched-Matched Coverage
GRP78_HUMAN 78 kDa glucose-regulated protein 391 1.60E-035 91 - 46 58%
ENOA_HUMAN Alpha-enolase 327 4.00E-029 82 - 34 82%
GRP78_HUMAN 79 kDa glucose-regulated protein 302 1.30E-026 64 - 32 47%
HSP7C_HUMAN Heat shock cognate 71 kDa protein 294 8.10E-026 70 - 39 48%
VIME_HUMAN Vimentin 290 2.00E-025 64 - 33 63%
ENOA_HUMAN Alpha-enolase 286 5.10E-025 82 - 34 82%
PDIA1_HUMAN Protein disulfide-isomerase 252 1.30E-021 77 - 30 55%
ANXA2_HUMAN Annexin A2 249 2.60E-021 65 - 31 72%
TBB5_HUMAN Tubulin beta chain 247 4.00E-021 73 - 32 62%
ANXA4_HUMAN Annexin A4 233 1.00E-019 50 - 25 59%
EFTU_HUMAN Elongation factor Tu, mitochondrial 217 4.00E-018 44 - 22 52%
TPIS_HUMAN Triosephosphate isomerase 206 5.10E-017 42 - 17 69%
VIME_HUMAN Vimentin 206 5.10E-017 62 - 23 50%
PGAM1_HUMAN Phosphoglycerate mutase 1 205 2.10E-016 41 - 18 58%
ATPB_HUMAN ATP synthase subunit beta, mitochondrial 193 1.00E-015 84 - 44 72%
ACTG_HUMAN Actin, cytoplasmic 2 192 1.30E-014 50 - 20 48%
PUR9_HUMAN Bifunctional purine biosynthesis protein PURH 191 1.60E-015 49 - 22 45%
KCRB_HUMAN Creatine kinase B-type 178 3.20E-014 50 - 19 48%
EF2_HUMAN Elongation factor 2 154 8.10E-012 67 - 26 33%
HYOU1_HUMAN Hypoxia up-regulated protein 1 154 8.10E-012 38 - 19 22%
KCRB_HUMAN Creatine kinase B-type 154 8.10E-012 50 - 19 48%
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A 150 2.00E-011 45 - 16 81%
GELS_HUMAN Gelsolin 147 4.00E-011 46 - 19 30%
VINC_HUMAN Vinculin 145 6.40E-011 36-19 20%
WDR1_HUMAN WD repeat-containing protein 1 144 8.10E-011 46 - 16 31%
EZRI_HUMAN Ezrin 131 1.60E-009 60 - 26 34%
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B 129 2.60E-009 42 - 21 33%
TBA1C_HUMAN Tubulin alpha-1C chain 127 4.00E-009 45 - 13 37%
PRDX1_HUMAN Peroxiredoxin-1 126 5.10E-009 53 - 18 58%
PDIA3_HUMAN Protein disulfide-isomerase A3 125 6.40E-009 47 - 15 28%
GRP75_HUMAN Stress-70 protein, mitochondrial 123 1.00E-008 81 - 34 43%
DHSA_HUMAN Succinate dehydrogenase flavoprotein subunit 122 3.30E-007 39 - 17 21%
RSSA_HUMAN 40S ribosomal protein SA 121 1.60E-008 37 - 11 34%
HS90B_HUMAN Heat shock protein HSP 90-beta 119 2.6e-08 44 - 19 27%
ESTD_HUMAN S-formylglutathione hydrolase 114 8.10E-008 25 - 11 41%
TKT_HUMAN Transketolase 114 8.10E-008 52 - 19 32%
LDHB_HUMAN L-lactate dehydrogenase B chain 112 1.30E-007 43 - 20 36%
AL1A1_HUMAN Retinal dehydrogenase 1 110 2.00E-007 58 - 19 34%
IPYR_HUMAN Inorganic pyrophosphatase 110 2.00E-007 22 - 9 35%
DDX3X_HUMAN ATP-dependent RNA helicase DDX3X 108 3.20E-007 23 - 13 20%
DHE3_HUMAN Glutamate dehydrogenase 1, mitochondrial 107 4.00E-007 38 - 13 29%
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 107 4.00E-007 55 - 13 42%
ACON_HUMAN Aconitate hydratase, mitochondrial 105 6.40E-007 54 - 23 30%
ML12A_HUMAN Myosin regulatory light chain 12A 105 6.40E-007 32 - 11 63%
RIR1_HUMAN Ribonucleoside-diphosphate reductase large subunit 101 1.60E-006 28 - 15 18%
EF2_HUMAN Elongation factor 2 99 2.60E-006 60-20 29%
QCR1_HUMAN Cytochrome b-c1 complex subunit 1, mitochondrial 98 3.30E-006 45 - 15 29%
CNN2_HUMAN Calponin-2 96 4.50E-006 51 - 13 48%
PCBP1_HUMAN Poly(rC)-binding protein 1 94 8.30E-006 39 - 14 44%
IMMT_HUMAN Mitochondrial inner membrane protein 92 1.30E-005 34 - 13 20%
CAPG_HUMAN Macrophage capping protein 91 1.80E-005 41 - 11 30%
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enolase A, triosephosphate isomerase and L-lactate
dehydrogenase B. We consider that the expression of
this group of proteins could be due to the cancerous
cells’ need to divide their incoming nutrients between
energy production and macromolecular biosynthesis to
support cell growth and DNA replication. This increase
in cell metabolism has been described in cancer cells,
which exhibit a much higher intake of glucose than nor-
mal cells, as well as increased rates of glycolysis and lac-
tate production even in the presence of oxygen [23-26].
Another protein detected by us as a member of the
“central core of cervical cancer” was galectin-1. Remark-
ably, very recently it was reported that cells can stimu-
late tumor angiogenesis by secretion of this protein, and
it was previously found in the vasculature of many
human tumors, including colon, head and neck, lung,
prostate, and oral cancers [27,28]. All of the proteins
identified as members of the “central core of cervical
cancer” are summarized in Table 1.
14-3-3ζ is a Hub in our protein-protein interaction
network
We performed a theoretical interactome (Figure 2) using
the Cytoscape plugin, Bisogenet, to add the experimen-
tally verified interactions between the 66 identified pro-
teins. This plugin employs the SysBiomics database
which integrates information from the INTACT [29],
BIOGRID [30], MINT [31], DIP [32], BIND [33] and
HPRD [34] databases.
Even though we identified 66 members of the central
core of cervical cancer, we were able to integrate into a
network only half of them because of a lack of experi-
mental evidence supporting PPIs. Notably, through a
topological analysis carried out on this network, we
found that the 14-3-3ζ protein features as a highly inter-
connected node (Figure 2). Additionally, western blot
analysis confirmed that all cervical cancer cell lines
express high protein levels of 14-3-3ζ. In contrast, no
blot of this protein was found in our control (Figure 3).
Afterwards, we expanded the PPI network as a way to
integrate all the proteins of the central core, in order to
obtain a coherent output which could be related in its
entirety to the neoplastic phenotype. It also served the
purpose of broadening our perspective and strengthen-
ing the statistical significance of our results.
The network expansion was performed considering
the experimentally obtained proteins as bait; the expan-
sion criterion was to include proteins that have a direct
experimental interaction in the databases, and were con-
nected via a shortest path of 1 to our proteins. This
resulted in a network of 1,321 nodes and 9,666 edges
(Figure 4).
We considered that the network expansion would
allow us to place the entities belonging to our central
core in a broader context, specially because the amount
of proteins that were identified represent a small frac-
tion of all the entities responsible for the phenotype.
We also expected to observe the same topological phe-
nomena in the expanded network as we did in the net-
work composed solely of cervical cancer-specific
proteins.
A connectivity distribution analysis allowed us to
identify those proteins that highly interact with others,
defined as the hubs of the expanded network. This
pointed once again to the multifunctional regulator of
cell signal transduction and adaptor protein, 14-3-3ζ,
followed by 14-3-3g with less than half the number of
interactions. Also, we calculated the betweenness of all
the proteins in the network, because it is a feature
Table 1 Proteins identified as members of the “central core of cervical cancer” (Continued)
TCTP_HUMAN Translationally-controlled tumor protein 91 1.80E-005 19 - 8 40%
PSB4_HUMAN Proteasome subunit beta type-4 89 1.70E-003 20 - 7 34%
TERA_HUMAN Transitional endoplasmic reticulum ATPase 88 3.10E-005 49 - 15 21%
K2C1_HUMAN Keratin, type II cytoskeletal 1 87 3.70E-005 46 - 13 29%
LEG1_HUMAN Galectin-1 84 7.70E-005 41 - 8 51%
1433Z_HUMAN 14-3-3 protein zeta/delta 80 2.30E-004 43 - 14 54%
LMNA_HUMAN Prelamin-A/C 78 3.40E-004 37 - 11 22%
HNRPL_HUMAN Heterogeneous nuclear ribonucleoprotein L 77 4.10E-004 27 - 13 16%
TCPH_HUMAN T-complex protein 1 subunit eta 77 4.00E-004 36 - 15 30%
OSBL8_HUMAN Oxysterol-binding protein-related protein 8 73 1.10E-003 56 - 13 21%
TCPE_HUMAN T-complex protein 1 subunit epsilon 71 1.70E-003 30 - 11 23%
HYOU1_HUMAN Hypoxia up-regulated protein 1 70 2.20E-003 28 - 13 14%
PSA5_HUMAN Proteasome subunit alpha type-5 69 2.70E-003 17 - 6 25%
FOXP3_HUMAN Forkhead box protein P3 68 3.40E-003 41 - 12 34%
The entry name corresponds to the UniProt database, the score and expect value were obtained from the search engine Mascot. The expect value is the number
of matches with equal or better scores that are expected to occur by chance alone. Score as -10*LOG10(P), where P is the absolute probability. The lower the
expectation value, the more significant the score.
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network structure and global network topology, besides
representing a measure of a node’s influence over infor-
mation transfer [35,36]. The proteins with the highest
betweenness were 14-3-3ζ, vimentin and vinculin, part
of our central core of cervical cancer proteins, which is
consistent with their role as bait proteins. However,
there were also non-bait nodes that featured among the
proteins with highest betweenness, such as ubiquitin
and 14-3-3g; thus, supporting the notion that the
betweenness metric, though biased in this case, is still a
valid metric of essentiality and robustness.
The enrichment analysis of gene ontology level 3 cate-
gory of biological processes shows 16 overrepresented
GOs (Table 2); the enriched KEGG pathway-based ana-
lysis shows 16 significant pathways (Table 3). Although
both enrichments are of great value for the analysis of
Figure 2 Network Reconstruction. Network of differentially expressed proteins in cervical cancer cell-lines compared to a non-cancerous
control. The connections between proteins represent experimentally verified protein-protein interactions between 33 out of the 66 proteins
identified in this study. The proteins not included in this network do not have experimentally proven interactions. The network was constructed
using Cytoscape and the plugin Bisogenet.
Figure 3 Overexpression of 14-3-3ζ. The expression levels of 14-
3-3ζ in the six cervical cancer cell lines were assessed by western
blot analysis. Whole brain extract was used a positive control,
because 14-3-3ζ has a strong expression in this tissue. a-Tubulin
was used as a loading control (Data not shown).
Higareda-Almaraz et al. BMC Systems Biology 2011, 5:96
http://www.biomedcentral.com/1752-0509/5/96
Page 6 of 16the biological significance of our proteins, these have the
limitation of considering the same protein or set of pro-
teins as part of different, and sometimes unrelated, pro-
cesses or pathways (Table 3). Consequently, results
should be carefully assessed before making further
interpretations.
There are common regulatory features among the
proteins of the expanded network
Using the information generated by the ENCODE pro-
ject, we searched among the transcription factors (TF)
that had chromatin immunoprecipitation-sequencing
(ChIP-Seq) data available, for overrepresented binding
sites of a given TF in the genes of our expanded net-
work (Figure 1). We evaluated for enrichment by con-
sidering binding sites that were located up to 700 bp
upstream or 300 bp downstream of all the transcription
start sites reported in the GENCODE database and that
had a score larger than 750. We considered these 1,000
bp as the promoter sequence, because it has been
reported to be the region of highest ChIP-Seq peak con-
centration in previous studies [37].
For the promoters of genes that belong to our
expanded network, we focused again on the information
provided in GENCODE. Out of the 1,321 nodes in the
network we retrieved 1,431 promoters corresponding to
957 unique genes of the network. We found that the
transcription factors E2F1 (p-value of 4.81E-13], TCF4
(p-value of 1.46E-12], c-Myc (p-value of 5.52E-11), Max
(p-value of 9.77E-11), E2F6 (p-value of 1.17E-10) and
NFKB (p-value of 5.02E-10) were the most significantly
overrepresented by a hypergeometric test (Table 4).
Importantly, the ChIP-Seq assays of the E2F1, c-Myc
and Max transcription factors were performed on the
HeLa-S3 cell line http://genome.ucsc.edu/. The fact that
these experiments were performed in one of the cell
Figure 4 Network Extension. Expanded network taking identified proteins as bait. Proteins belonging to our core of differentially expressed
proteins were used as bait to fish protein-protein experimental interactions by adding neighbors of input nodes to a distance of up to one
protein. This resulted in a network of 1,321 nodes and 9,666 edges. The network was expanded using Cytoscape and the plugin Bisogenet. Pink
nodes represent the bait proteins, while the blue nodes correspond to the proteins that were included as a result of the network expansion.
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sis additional validity, because the cellular context is
unlikely to be significantly different.
Also, it is noteworthy to mention that we performed a
similar analysis, but using the promoter regions as
reported in the Transcriptional Regulatory Element
Database (TRED] [38] and employing the SwitchGear
Database for the acquisition of the transcription start
sites. Using this approach, we obtained a similar enrich-
ment (Table 5).
Among the overrepresented TFs, we consider that the
presence of c-Myc is remarkable because it is in agree-
ment to what is currently known about cancer cells in
general. Also, c-Myc’s primary binding partner for gene
activation is Max, so that the presence of this protein is
complementary to c-Myc’s activity. The mechanisms
that make of c-Myc a very powerful oncogene are not
very clear; however, there is evidence that indicates that
the activation of c-Myc correlates with approximately
70% of human cancers [39].
Table 2 Enriched gene ontology level 3 categories of biological processes
gene ontology term set size candidates contained p-value q-value
GO:0006986 response to unfolded protein 73 8 3.11E-009 7.03E-007
GO:0070841 inclusion body assembly 13 4 4.26E-007 4.82E-005
GO:0006091 generation of precursor metabolites and energy 363 11 2.02E-006 1.52E-004
GO:0032507 maintenance of protein location in cell 80 6 3.14E-006 1.77E-004
GO:0016052 carbohydrate catabolic process 132 7 4.67E-006 1.93E-004
GO:0051651 maintenance of location in cell 87 6 5.13E-006 1.93E-004
GO:0012501 programmed cell death 1338 20 7.18E-006 2.32E-004
GO:0010941 regulation of cell death 1136 18 1.06E-005 2.99E-004
GO:0046907 intracellular transport 855 15 2.08E-005 5.21E-004
GO:0002349 histamine production involved in inflammatory response 2 2 2.56E-005 5.25E-004
GO:0043455 regulation of secondary metabolic process 2 2 2.56E-005 5.25E-004
GO:0002443 leukocyte mediated immunity 184 7 4.05E-005 7.64E-004
GO:0044248 cellular catabolic process 1028 16 4.56E-005 7.92E-004
GO:0050777 negative regulation of immune response 40 4 4.91E-005 7.93E-004
GO:0070727 cellular macromolecule localization 610 12 5.29E-005 7.98E-004
GO:0051235 maintenance of location 133 6 5.79E-005 8.18E-004
Set size refers to the number of entities that have a Uniprot ID as stated in the corresponding GO category at the ConsensusPathDB site. The number of
candidates contained refers to amount of proteins identified in this study that appear as part of the GO category. P-values are calculated according toa
hypergeometric test; q-values represent p-values corrected for multiple testing using the false discovery rate method.
Table 3 Enriched KEGG pathway-based sets
pathway name set size candidates contained p-value q-value pathway source
Small cell lung cancer 84 37 8.67E-009 1.43E-006 KEGG
Protein processing in endoplasmic reticulur 164 57 4.21E-008 3.47E-006 KEGG
Pathways in cancer 325 94 8.81E-008 4.05E-006 KEGG
Apoptosis 87 36 9.82E-008 4.05E-006 KEGG
Neurotrophin signaling pathway 125 46 1.24E-007 4.10E-006 KEGG
T cell receptor signaling pathway 108 41 2.25E-007 6.19E-006 KEGG
Focal adhesion 199 62 9.45E-007 2.23E-005 KEGG
Prostate cancer 89 33 6.11E-006 1.26E-004 KEGG
Pathogenic Escherichia coli infection 54 23 1.13E-005 2.07E-004 KEGG
Endometrial cancer 52 22 1.99E-005 3.28E-004 KEGG
Shigellosis 61 24 3.61E-005 5.42E-004 KEGG
Non-small cell lung cancer 54 22 4.03E-005 5.54E-004 KEGG
Proteasome 44 19 5.17E-005 6.56E-004 KEGG
Bacterial invasion of epithelial cells 70 26 5.59E-005 6.59E-004 KEGG
B cell receptor signaling pathway 75 27 7.62E-005 8.38E-004 KEGG
Leukocyte transendothelial migration 116 37 8.27E-005 8.53E-004 KEGG
Set size refers to the number of entities that have a Uniprot ID as stated in the corresponding KEGG pathway-based set at the ConsensusPathDB site. The
number of candidates contained refers to amount of proteins which are part of the extended network and appear as part of the pathway. P-values are calculated
according to a hypergeometric test; q-values represent p-values corrected for multiple testing using the false discovery rate method.
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in cancer is that the genes it induces represent the pri-
mary response of nearly all signal transduction path-
ways known to be involved in cancer [39]. Likewise,
Nilsson et al, [39] have suggested that a loss in c-
Myc’s ability to induce apoptosis can convert c-Myc
into a pure promoter of cell growth and transforma-
tion. Concordantly, the abrogation of p53 function,
which is the protein responsible for executing c-Myc’s
apoptotic response, has been substantiated in all HPV
positive cell lines, as well as the HPV negative cell line,
C33-A [40].
The last factor, E2F1, controls cell-cycle progression
and DNA replication and it has been shown to be
induced by c-Myc’s activity [41]. E2F1 has also been
implicated in c-Myc mediated down regulation of
p27
KIP1, which is a cyclin-dependent kinase inhibitor
[42]. Finally, polymerase 2 featured as the DNA-binding
protein with the most significant p-value, thereby pro-
viding us with a notion of the genes of the network that
are being transcribed (Tables 4 and 5).
Discussion
We performed a comprehensive analysis that stems
from data obtained by proteomic techniques, using per-
spectives of biological networks and the annotated data
of the human genome and large-scale sequencing tech-
niques available to the public as a tool for building
models to infer biological behaviors (Figure 1).
As defined in this study, the “central core of cervical can-
cer” does not describe the immortalization process directly;
rather, it represents processes involved in maintaining a
viable and proliferating cell. Table 2 presents the biological
processes that are enriched in our core set of proteins and
as can be seen, these are suggestive of a malignant pheno-
type, where the main GOs are those related to UPR, meta-
bolism, catabolic processes, maintenance of cell-location
and cell death. These observations are consistent with our
initial conjectures, since we considered that using the
HaCaT cell line as a control would allow us to distinguish
between immortalization and transformation, because
HaCaT is an immortalized cell line with a stable kariotype
and phenotype, which is non-tumorigenic.
Table 4 Significantly overrepresented transcription factors identified by ENCODE ChIP-Seq peaks based on the
GENCODE Database
Transcription Factor cell line tissue of origin peaks near TSS of the gene
of the extended network
peaks near TSS of all the
GENCODE genes
p-value
E2F1 HeLa-S3 cervical 187 1445 4.81E-013
TCF4 HCT-116 colorectal 244 2059 1.46E-012
Pol2 HeLa-S3 cervical 312 2878 3.93E-011
c-Myc HeLa-S3 cervical 123 880 5.52E-011
Max HeLa-S3 cervical 161 1266 9.77E-011
E2F6 k562 Leukemia 265 2379 1.17E-010
NFKB GM12878 Lymphoblastoid 111 794 5.02E-010
The peaks were mapped to regions corresponding to the promoter sequences as considered for this study (-700, 300 bp), based upon transcription start sites
(TSS) annotated by GENCODE. Peaks near TSS of the genes of the extended network and all GENCODE genes refers to the amount of peaks found in the
promoter region. P-values were calculated by a hypergeometric test. Sample size was considered as the amount of genes that corresponded to the proteins of
the extended network. Population size was the number of annotated GENCODE entries that had a complete status and were separated by a distance of up to
500 base pairs.
Table 5 Significantly overrepresented transcription factors identified by ENCODE ChIP-Seq peaks based on the TRED
Database
Transcription Factor cell line tissue of origin peaks near TSS of the genes
of the extended network
peaks near TSS reported on SwitchGear p-value
Pol2 HeLa-S3 cervical 608 7766 2.15E-067
TCF4 HCT-116 colorectal 455 5543 1.93E-050
E2F6 k562 Leukemia 488 6343 1.12E-046
Max HeLa-S3 cervical 313 3375 2.90E-042
c-Myc HeLa-S3 cervical 250 2395 1.88E-041
NFKB GM12878 Lymphoblastoid 195 1802 6.78E-034
E2F1-HA HeLa-S3 cervical 315 4272 7.57E-024
ChIP-Seq peaks mapped to regions corresponding to the promoter sequences as considered for this study (-700, 300 bp), based upon transcription start sites
(TSS) annotated by SwitchGear. Peaks near TSS of the genes of the extended network and reported on SwitchGear refers to the amount of peaks found in the
corresponding promoter regions. P-values were calculated by a hypergeometric test. Sample size was considered as the amount of genes that corresponded to
the proteins of the extended network. Population size was the number of reported TSS reported on SwitchGear with a score greater than 20.
Higareda-Almaraz et al. BMC Systems Biology 2011, 5:96
http://www.biomedcentral.com/1752-0509/5/96
Page 9 of 16O n eo ft h es t u d i e st h a tu s e st h eH a C a Tc e l ll i n ea sa
control was performed by Choi, et al.[14]. The main dif-
ference between the latter study and our work, is that
they used cervix biopsies; this implies that there are
important differences in the intracellular and extracellu-
lar contexts of the biological model. Likewise, even
though the methodology they utilized only considers
samples with the same pathologic diagnosis, it is likely
that there is still an important amount of heterogeneity
in their samples due to inter-individual differences. As
e x p e c t e d ,w eo n l yf o u n do n ec o m m o np r o t e i na m o n g
the results of both studies: Vimentin. However, they
were able to identify a number of proteins that
strengthen our findings such as Amy-1, which stimu-
lates c-Myc’s E-box dependent transactivation activity
[43]; and Miz-1, which must be inhibited in order for c-
Myc to mediate apoptosis [44]. Another result that sup-
ports our findings is that they observed a downregula-
tion of 14-3-3s, which plays an opposite role in cell
growth, compared to 14-3-3ζ [45]. Finally, they also
found a clear overexpression of chaperone proteins, dif-
ferent from the ones in our central core.
The acquisition of the reported interactions between
the identified proteins provided a first insight of the key
elements in the neoplastic dynamics, and became the
meter that allowed us to judge the validity of later ana-
lysis, by seeking an overall agreement between the origi-
nal and the extended network. It is noteworthy that for
the small network the highest interconnected node was
14-3-3ζ, and this was not lost when we expanded the
network. Also, both networks are enriched in similar
processes.
When analyzing the extended network it is apparent
that 6 of the members of the 14-3-3 protein family (ζ, g,
b, τ, s and ε) feature among the highest interconnected
nodes. This is consistent with the biological role of the
members of this protein family as signal transduction
molecules [46]. The identification of 14-3-3ζ and its role
as a hub and as a bottleneck in the PPI network is parti-
cularly relevant because it is known to be involved in
three important cellular processes: cell cycle regulation,
signal transduction and regulation of apoptosis [47-50].
Furthermore, we noticed that the 14-3-3ζ protein,
which features as the highest interconnected node of
both our networks, did not posses any ChIP-Seq peak
near the transcription start site of its encoding gene.
Upon more careful inspection throughout the entire
length of the gene, we noticed that there appears to be
a regulatory region inside the transcript. Importantly, we
found binding sites of c-Myc, Max, E2F1 and Pol2 very
close to each other. This has lead us to believe that one
of the mechanisms that lead to 14-3-3ζ’s overexpression
is mediated by c-Myc and E2F1 (Figure 5).
It was previously reported by Jonsson and Bates [13]
that cancer proteins exhibit a significantly different net-
work topology when compared to proteins unrelated to
cancer; as well as a higher ratio of promiscuous struc-
tural domains. This is in agreement with what is known
about the members of the 14-3-3 protein family, which
have been described as signal integrators, amplifying
strong signals and filtering out weaker conflicting ones
to achieve a meaningful, coordinate biological output,
such as cell death or survival [51].
Also, there is strong evidence that the overexpression
of 14-3-3ζ promotes p53 degradation by the proteoso-
mal route [52], which is increased by the action of E6 in
HPV-infected cells [7]. An enhanced turn-over rate of
the p53 protein and the pleiotropic effects consequence
of the increased number of 14-3-3ζ proteins, which are
involved in a large number of cellular processes, could
be the reason why not all infections develop into cancer
and most of them are subclinical: c-Myc could be acti-
vating 14-3-3ζ in a differential manner. Therefore, we
consider that we posses sufficient evidence to suggest
the role of 14-3-3ζ in cervical cancer cell lines as the
determining factor that can ultimately dictate the fate of
a cell, regardless of it being infected with HPV; and
cause it to undergo cell cycle deregulation onto malig-
nant transformation (Figure 5).
Likewise, when we performed a biological pathway
enrichment, which we consider the best way to perform
a functional analysis, we found consistent results. To do
this, we used the ConsensusPathDB site to find overre-
presented KEGG pathways in the proteins of our
extended network. The enrichment analysis showed an
overrepresentation of survival factors of apoptosis path-
ways and focal adhesion that is related to invasion and
metastasis, two of the most important and well-docu-
mented hallmarks of cancer; as well as various estab-
lished cancer pathways like small cell lung cancer,
prostate cancer, endometrial cancer and pathways in
cancer (Table 3). This was obviously expected and helps
to strengthen our analysis, indicating that the central
core of cervical cancer, and its subsequent expansion
proposed in the PPI interaction network, still retain
those proteins that are closely related to the neoplastic
process.
However, there are other pathways that do not present
such a straightforward connection to cancer, such as the
neurotrophin and T-cell receptor signaling pathways,
bacterial infections and proteasome pathways. We can
only speculate about their meaning, as the cellular
stress, chronic inflammation, turnover of proteins, cell
survival and evasion of the immune system are other
features related to the progression and maintenance of
tumorigenesis.
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dynamics of the system, we also performed an enrich-
ment analysis of transcription factor binding sites
among the promoters of the genes of our extended net-
work. We focused on the three transcription factors that
complied with both of the following: those which were
significantly overrepresented among the promoter
regions of the genes of the proteins of our network and
those in which the corresponding ChIP-Seq assays were
carried out on the HeLa-S3 cell line http://genome.ucsc.
edu/. The resulting transcription factors are: E2F1, c-
Myc and Max. We believe that together, these transcrip-
tion factors bring an overall feeling of coherence to the
network because the overexpression of c-Myc is
Figure 5 Model of Action of c-Myc, E2F1 and 14-3-3ζ. Model of the downstream events product of the overexpression and/or amplification
of c-Myc, and its collaboration with the transcription factor E2F1. c-Myc promotes the expression of proteins that lead to survival and
proliferation through processes such as metabolism, protein biosynthesis and transcription factors. Likewise, it enables the expression of proteins
involved in epithelial mesenchymal transition. E2F1 and c-Myc work together to promote the expression of Cyclins and E2F factors that boost
the transition between G1 and S phases of mitosis, as well as the expression of 14-3-3ζ and Bcl-2. Bcl-2 is an antiapoptotic protein that prevents
the release of cytochrome c. The overexpression of 14-3-3ζ results in instability and degradation of p53, increased cell proliferation, and
cytoplasmic sequestration of BAD with what brings drastic decrease of apoptosis.
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Page 11 of 16widespread in human cancers, and specifically in cervical
cancer [53]. Moreover, there is evidence that E2F1 is
activated by the E7 protein of HPV-16 in a pRB-inde-
pendent manner [54], apart from its pRB-dependent
activation, which in the case of HPV infected cells is
also promoted by pRB inactivation by viral oncoprotein
E7. In the context of cervical cancer, it has been
reported that an overexpression of E2F1 can drive quies-
cent cells through G1 into S-phase of the cell cycle, ulti-
mately leading to apoptosis or neoplastic transformation.
E2F1 has been shown to be an inhibitor of c-Myc’s
activator, b-catenin, by means of the Wnt pathway
[55,56]. We also found a clear overrepresentation of the
TCF4 transcription factor in the genes of our network.
This contradicts our previous finding because TCF4
functions in the activation of the Wnt pathway, and
therefore, of c-Myc. However, we had to consider that
all the published works that point to E2F1 as an inhibi-
tor of c-Myc have been performed in colorectal cancer.
Likewise, the evidence of enrichment of TCF4 binding
sites was performed in the HCT-116 cell line and so we
do not posses information about the function of this
transcription factor in cervical cancer.
It has been observed in human foreskin keratinocyte
and fibroblast (HFK and HFF) cells that the genetic
background of the cell type can be determinant for the
outcome of altered gene expression. This is the case of
HFF which cannot be immortalized by the mere addi-
tion of oncoproteins E6 and E7, unlike the HFK cells,
due to a differential turnover of c-Myc [57]. Moreover,
as pointed by Bernards [58] in the context of colorectal
cancer pRB is more likely to be acting as an oncoprotein
than as a tumor suppressor, which is clearly not the case
in cervical cancer. Considering all the previous evidence,
we can only infer that the proteins pRB and E2F1 are
acting with opposing roles in cervical cancer, as com-
pared to colorectal cancer.
On the other hand, there are reports of E2F1 and c-
Myc overexpression in cervical cancer, which also corre-
late their expression with advanced states of the disease
[59]. Also, genetic studies of the E2F promoters have
shown that these genes are induced by c-Myc, depen-
dent on the E box sites. Coordinately, all data point to a
model where c-Myc is activated by means different from
the canonical pathways and is working with E2F1 to
promote the neoplastic phenotype.
The possible scenario of molecular events in cervical
cancer suggested by our study portrays the evasion of
apoptosis mediated in two ways, first, the sequestration
of the pro-apoptotic protein BAD by 14-3-3ζ [60] and
the overexpression of the anti-apoptotic protein Bcl-2
managed by the interaction of c-Myc and E2F1 [61].
Evasion of apoptosis by these routes can be supported
by the interaction of viral oncoproteins E6 and E7 with
tumor suppressor proteins p53 and pRb, when there is
persistent infection with high-risk HPV. Simultaneously,
these oncoproteins are able to promote significant
increase in proliferation, and immortalize cells through
the activation of hTERT [62].
The expression of E2F factors and cyclins facilitated
by c-Myc, together E2F1 leads to a quick transition
from the G1 to the S phase of the cell cycle, and the
consequent boost in growth and cell proliferation [63].
Finally, c-Myc overexpression allows a significant
increase in cell proliferation by key roads, such as protein
biosynthesis, central metabolism, the expression of tran-
scription and cell cycle factors [64] and expression of 14-3-
3ζ. All of these contribute to facilitate the transition from
G1 to S phase [65]. c-Myc’s mediated expression of Ezrin
[66] also promotes epithelial mesenchyma transition, facili-
tated by the overexpression of vimentin [67] (Figure 5).
Conclusions
Our results suggest a phenotype shared by the six cervi-
cal cancer cell lines as a result of the overexpression of
c-Myc, helped by E2F1, which in turn allows the overex-
pression of 14-3-3ζ and other proteins of the “central
core of cervical cancer”. This signal transduction protein
has been reported in other models of cancer as being
responsible for malignant transformation and the deci-
sion between life and death of cells (Figure 5).
Methods
Cell culture
The CaSki, HeLa, SiHa, C-33A, ViBo and CaLo cell lines
were provided by the oncology laboratory of the Centro
Medico Siglo XXI which belongs to the Instituto Mexi-
cano del Seguro Social. The HaCaT cell line was
donated by the Centro de Investigación Sobre Enferme-
dades Infecciosas, which belongs to the Instituto Nacio-
nal de Salud Pública. All cell lines were cultured in
RPMI-advanced 1640 serum-free media (Gibco BRL,
USA) with red phenol and antibiotic-antimycotic solu-
tion (10,000 units penicillin, 10 mg streptomycin, and
25 μg amphotericin B per mL), supplemented with 1%
fetal bovine serum (Invitrogen, Carlsbad, CA) and 200
mM of GlutaMAX (Invitrogen). The cells were incu-
bated in 5% of CO2 and humidity saturation at 37°C in
culture flasks of 75 cm
2 (Nalge Nunc International,
Rochester, NY). Cells were harvested at 70% confluence
with Verseno solution (Tris base 25 mM, NaCL 136.8
mM, KCl 5.36 mM, EDTA 1 mM pH7.7) and washed 3
times in phosphate buffer saline (0.1 M sodium phos-
phate and 0.15 M NaCl in one liter, pH 7.2).
Proteomic Analysis
Protein extraction and two dimensional gel electrophor-
esis were done as previously described [68]. Gels were
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Page 12 of 16dyed in colloidal coomasie [69] and scanned in a GS-800
densitometer (Bio-Rad, Hercules, CA). Digital images
were analyzed and compared using the PDQuest 8.0.1
software (Bio-Rad). Each experiment was done in tripli-
cate. Once the digital image of each gel was compared
against the rest, the electrophoretic entities of interest
were cut, alkylated, reduced, digested and automatically
transferred to a MALDI analysis target by a Proteineer
SP II and SP robot using the SPcontrol 3.1.48.0 v soft-
ware (Bruker Daltonics, Bremen, Germany), with the aid
of a DP Chemicals 96 gel digestion kit (Bruker Daltonics)
and processed in a MALDI-TOF Autoflex (Bruker Dal-
tonics) to obtain a mass fingerprint. We performed 100
satisfactory shots in 20 shotsteps, the peak resolution
threshold was set at 1,500, the signal/noise ratio of toler-
ance was 6, and contaminants were not excluded. The
spectrum was annotated by the flexAnalysis 1.2 v SD1
Patch 2 (Bruker Daltonics). The search engine MASCOT
[70] was used to compare the fingerprints against the
UNIPROT [71] release 2010_09 database with the follow-
ing parameters: Taxon-Human, mass tolerance of up to
500 ppm, one miss-cleavage allowed, and as the fixed
modification Carbamidomethyl and oxidation of methio-
nine as the variable modification.
Western blot analysis
Antibodies for immunoblotting were as follows: anti-14-
3-3ζ human polyclonal (Imgenex, San Diego, CA) and
anti-a-tubulin mouse monoclonal (Zymed Laboratories,
South San Francisco. CA). Equal amounts of protein
samples were subjected to SDS-PAGE, and transferred
to a polyvinylidene difluoride membrane (Immobilon-P,
Millipore Corp., Billerica, MA, USA). After blocking
with 5% skimmed milk, the membrane was washed in
TBS-tween 20%, and incubated with a primary antibody,
followed by a AP-conjugated second antibody anti-rabitt
or anti-mouse (Zymed). Blots were detected by chromo-
genic substrate BCIP/NBT (Zymed).
Network Reconstruction
The network reconstruction was performed with the aid
of the Cytoscape [72] Plugin, BisoGenet [73], using the
identified proteins as bait nodes and adding edges with
the following parameters: Organism> Homo sapiens,
protein identifiers only; Data Settings>protein-protein
interactions; all data sources and all experimental meth-
ods; method> By adding edges connecting input nodes
and as Output> Proteins.
Network Extension
The primary network was extended by performing the
bioinformatic bait technique, using the Cytoscape Plugin
Bisogenet with the expand network option and the pre-
vious parameters, except that the method used was By
adding neighbors of input nodes to a distance of one.
The resulting network was subjected to a centrality
measure analysis with the Plugin CentiScaPe1.1 [74].
Pathway and GO enrichment analysis
We performed an enrichment analysis of pathway-based
sets of proteins considering all the nodes of our
extended network. Enrichment was done employing
ConsensusPathDB [75], of the Max Planck Institute for
Molecular Genetics, by using the overrepresentation
analysis online tool. As input, we uploaded the UNI-
PROT protein identifiers of all the elements of the
extended network. We searched against pathways as
defined by KEGG [76], with a minimal overlap with the
input list of 5 and a p-value cutoff of 0.0001.
Also, employing the same website and the same analy-
sis tool, we performed an enrichment analysis based on
Gene Ontology [77] level 3 category of biological pro-
cesses. For this analysis, we considered only the identi-
fied core proteins and set the p-value cutoff on 0.00001.
Promoter Analysis
To help us uncover some of the regulatory dynamics
underlying cervical cancer we downloaded the Gencode
Genes-ENCODE Gencode Gene Annotations table
(wgEncodeGencodeManual V3) [78,79] from the Univer-
sity of California Santa Cruz Genome Browser website
[80]. From this table we retrieved the transcription start
site of all GENCODE genes with a score greater than
750, as well as its associated ENSEMBL Transcript ID
and gene name. Because some transcripts present sev-
eral nearby start sites, we also set a filter that only con-
siders start sites located at a distance greater than 500
bp, this reduced the amount of entries considered to
18,534. Promoter sequences were defined as 700 bp
upstream and 300 bp downstream of the transcription
start site. The promoter locations corresponding to the
genes of the proteins of our network were identified
based on the ENSEMBL transcript ID as well as the
gene names and synonyms stated in the UNIPROT data
of those proteins.
Peak information was downloaded from the Yale tran-
scription factor binding site (TFBS) track of the
ENCODE Project [80] with a preference for the assays
from the HeLa-S3 cell line. A peak was considered to be
inside the promoter if the mid-point of the peak was
inside the 1,000 bp reported as the promoter sequence.
Hypergeometric tests were performed in order to assess
the significance of our findings. Sample size was consid-
ered as the number of promoters that contain TFBS. All
methodology is summarized in Figure 1.
The data associated with this manuscript may be
downloaded from ProteomeCommons.org Tranche
using the following hash:
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QW/ldOSRKlStNTsd5aKw9dla
58 iAmEm8L7H8jAZ7A+TR2SNpTg+EUAAAAAAA
AB8Q==
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